AGP Executive Report
Last update: 5 hours agoM&A in Pharma: SERB Pharmaceuticals is buying Idefirix® (imlifidase) rights from Hansa Biopharma for €115m, securing exclusive EU/UK/Switzerland/Norway/Liechtenstein and MENA development and commercialisation for a kidney-transplant desensitisation drug aimed at highly sensitised patients. Bilateral Business Push: PM Narendra Modi’s Norway visit is turning into a trade-and-energy sprint: leaders agreed a “Green Strategic Partnership” on clean energy, climate resilience, blue economy and green shipping, while also pointing to the India–EFTA TEPA deal (including Liechtenstein) as a blueprint for deeper investment and market access. Regulatory Friction Watch: EU steel tariffs are back in the spotlight after Brussels rejected Swiss criticism, arguing the EU can act autonomously outside the Swiss-EU stabilisation package. Local Execution Theme: Norwegian firms told Modi to fix “ground level” regulatory bottlenecks to make approvals faster. Cross-border Mobility: UK airports will expand e-gates for children aged eight and nine from July 8, potentially easing summer queues for families.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
